• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H2 2012 Product Image

B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H2 2012

  • Published: October 2012
  • 52 pages
  • Global Markets Direct

B-Cell Chronic Lymphocytic Leukemia – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for B-Cell Chronic Lymphocytic Leukemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for B-Cell Chronic Lymphocytic Leukemia. B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for B-Cell Chronic Lymphocytic Leukemia.
- READ MORE >

2
List of Tables 4
List of Figures 5
Introduction 6
REPORT COVERAGE 6
B-Cell Chronic Lymphocytic Leukemia Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for B-Cell Chronic Lymphocytic Leukemia 8
B-Cell Chronic Lymphocytic Leukemia Therapeutics under Development by Companies 10
B-Cell Chronic Lymphocytic Leukemia Therapeutics under Investigation by Universities/Institutes 11
Late Stage Products 12
Comparative Analysis 12
Mid Clinical Stage Products 13
Comparative Analysis 13
Early Clinical Stage Products 14
Comparative Analysis 14
B-Cell Chronic Lymphocytic Leukemia Therapeutics – Products under Development by Companies 15
B-Cell Chronic Lymphocytic Leukemia Therapeutics – Products under Investigation by Universities/Institutes 16
Companies Involved in B-Cell Chronic Lymphocytic Leukemia Therapeutics Development 17
Genzyme Corporation 17
Abbott Laboratories 18
GTC Biotherapeutics, Inc. 19
Ono Pharmaceutical Co., Ltd. 20
Alexion Pharmaceuticals, Inc. 21
B-Cell Chronic Lymphocytic Leukemia – Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Combination Products 23
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
samalizumab - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Campath + Fludara - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
alvocidib - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
alvocidib - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
alvocidib - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
alvocidib - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
ABT-263 + Rituximab - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Leukapheresis + Fludarabine + Cyclophosphamide + Autologous CD19 Specific T-cell Infusion - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 42
cediranib maleate - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
ABT-348 + Azacitidine - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
ONO-4059 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Anti-CD 19 CAR Autologous PBL - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
B-Cell Chronic Lymphocytic Leukemia Therapeutics – Drug Profile Updates 47
B-Cell Chronic Lymphocytic Leukemia Therapeutics - Dormant Products 48
B-Cell Chronic Lymphocytic Leukemia – Product Development Milestones 49
Featured News & Press Releases 49
Aug 24, 2012: TG Therapeutics Announces Poster Presentation For Ublituximab At 7th International Workshop On Waldenstrom's Macroglobulinemia 49
Jun 04, 2007: ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial In B-Cell Chronic Lymphocytic Leukemia 49
Appendix 51
Methodology 51
Coverage 51
Secondary Research 51
Primary Research 51
Expert Panel Validation 51
Contact Us 52
Disclaimer 52

List of Tables
Number of Products Under Development for B-Cell Chronic Lymphocytic Leukemia, H2 2012 8
Products under Development for B-Cell Chronic Lymphocytic Leukemia – Comparative Analysis, H2 2012 9
Number of Products under Development by Companies, H2 2012 10
Number of Products under Investigation by Universities/Institutes, H2 2012 11
Comparative Analysis by Late Stage Development, H2 2012 12
Comparative Analysis by Mid Clinical Stage Development, H2 2012 13
Comparative Analysis by Early Clinical Stage Development, H2 2012 14
Products under Development by Companies, H2 2012 15
Products under Investigation by Universities/Institutes, H2 2012 16
Genzyme Corporation, H2 2012 17
Abbott Laboratories, H2 2012 18
GTC Biotherapeutics, Inc., H2 2012 19
Ono Pharmaceutical Co., Ltd., H2 2012 20
Alexion Pharmaceuticals, Inc., H2 2012 21
Assessment by Monotherapy Products, H2 2012 22
Assessment by Combination Products, H2 2012 23
Assessment by Stage and Route of Administration, H2 2012 25
Assessment by Stage and Molecule Type, H2 2012 27
B-Cell Chronic Lymphocytic Leukemia Therapeutics – Drug Profile Updates 47
B-Cell Chronic Lymphocytic Leukemia Therapeutics – Dormant Products 48

List of Figures
Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia, H2 2012 8
Products under Development for B-Cell Chronic Lymphocytic Leukemia – Comparative Analysis, H2 2012 9
Products under Development by Companies, H2 2012 10
Products under Investigation by Universities/Institutes, H2 2012 11
Late Stage Products, H2 2012 12
Mid Clinical Stage Products, H2 2012 13
Early Clinical Stage Products, H2 2012 14
Assessment by Monotherapy Products, H2 2012 22
Assessment by Combination Products, H2 2012 23
Assessment by Route of Administration, H2 2012 24
Assessment by Stage and Route of Administration, H2 2012 25
Assessment by Molecule Type, H2 2012 26
Assessment by Stage and Molecule Type, H2 2012 27

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos